|2.||Pancreatic Fistula (Pancreatic Fistulas)
|1.||Yamaue, Hiroki: 13 articles (10/2015 - 01/2005)|
|2.||Bassi, Claudio: 13 articles (07/2015 - 06/2005)|
|3.||Lillemoe, Keith D: 12 articles (08/2015 - 11/2004)|
|4.||Sauvanet, Alain: 11 articles (10/2015 - 08/2004)|
|5.||Yeo, Charles J: 11 articles (06/2015 - 11/2004)|
|6.||Büchler, Markus W: 11 articles (01/2015 - 01/2002)|
|7.||Kawai, Manabu: 11 articles (03/2014 - 01/2005)|
|8.||Pitt, Henry A: 10 articles (08/2015 - 12/2007)|
|9.||Fujii, Tsutomu: 9 articles (11/2015 - 01/2006)|
|10.||Kodera, Yasuhiro: 9 articles (11/2015 - 01/2002)|
|1.||Octreotide (Sandostatin)FDA LinkGeneric
01/01/2013 - "Comment on the article by Droeser et al.: 'Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery'."
01/01/2012 - "Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery."
12/01/2007 - "The review revealed that perioperative octreotide is associated with a significant reduction in the incidence of pancreatic fistula after elective pancreatic surgery. "
12/01/2007 - "Perioperative octreotide is associated with a significant reduction in the incidence of pancreatic fistula after elective pancreatic surgery, with a relative risk of 0.59 (95% confidence interval 0.41-0.85, p = 0.004). "
12/01/1989 - "Sandostatin is effective in decreasing drainage from external pancreatic fistulas and may, therefore, facilitate their closure. "
|2.||Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
10/01/1993 - "Somatostatin analogs are useful in the management of pancreatic fistulas. "
10/01/2013 - "The aim of this study was to evaluate the efficacy of somatostatin in preventing pancreatic fistulas and improving postoperative outcomes after pancreatic resection. "
01/01/2012 - "Are somatostatin or its synthetic analogues helpful in reducing pancreatic fistula?"
08/01/2014 - "Studies have shown that somatostatin reduces the occurrence of postoperative pancreatic fistula. "
10/01/2013 - "Pancreatic fistula developed in 7 patients (3%) who received somatostatin versus 23 (8%) who did not receive somatostatin (P = .031). "
|3.||Fibrin Tissue Adhesive (Fibrin Sealant)IBA
11/01/2004 - "The pancreatic fistula rate in the fibrin glue arm of the study was 26% vs. 30% in the control group (p = not significant [NS]). "
07/01/2012 - "Prevalence of pancreatic fistula was not significantly different between the fibrin glue group and the non-fibrin glue group. "
07/01/2012 - "Does fibrin glue prevent biliary and pancreatic fistula after surgical resection?"
03/01/2011 - "We have developed a fibrin adhesive sealing method which covers the cut surface and parenchyma of the pancreas, to prevent pancreatic fistula. "
07/01/2007 - "No patients in the fibrin sealant group experienced pancreatic fistula, as compared with three patients (23%) in the no sealant group. "
10/01/2012 - "Our study shows that the combined use of a stapler and TachoComb decreased the incidence of pancreatic fistulas after LDP. "
01/01/2011 - "The use of TachoComb fibrin adhesive as a sealing method in duct-to-mucosa pancreaticojejunostomy is safe, reliable for the prevention of pancreatic fistula, and shows promise for all types of reconstruction following pancreaticoduodenectomy."
01/01/2011 - "Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy."
12/01/2015 - "Use of a Fibrinogen/Thrombin-Based Collagen Fleece (TachoComb, TachoSil) With a Stapled Closure to Prevent Pancreatic Fistula Formation Following Distal Pancreatectomy."
12/01/2015 - "The aim of this study was to evaluate the rate of clinically significant fistulas (International Study Group on Pancreatic Fistula grade B and grade C) after distal pancreatectomy using a fibrinogen/thrombin-based collagen fleece (TachoComb, TachoSil) with a stapled closure. "
09/01/1997 - "Determination of drainage fluid amylase levels is a simple and useful method for the prediction of pancreatic fistula formation and may help to plan appropriate management."
10/01/2015 - "We evaluated amylase levels in drainage fluid on postoperative days (POD) 1 and 3 and the incidence of postoperative PF according to International Study Group of Pancreatic Fistula (ISGPF) definitions. "
10/01/2015 - "This study to evaluate the utility of drain fluid amylase as a predictor of PF in patients undergoing pancreatic surgery based on the International Study Group of Pancreatic Fistula definitions of pancreatic fistula. "
11/01/2014 - "Previous studies demonstrate that drain fluid amylase on postoperative day 1 (DFA1) is predictive of pancreatic fistula. "
06/01/2008 - "Compared parameters between groups included background, incidence and grading of pancreatic fistula as judged by international study group of pancreatic fistula (ISGPF) criteria, duration until drain removal, and mean maximum level of drain amylase. "
08/01/1986 - "This study was designed to determine the role of endogenous and exogenous secretin in gastric inhibition and pancreatic stimulation by an acidified liver extract (LE) meal in conscious dogs prepared with chronic gastric and pancreatic fistulas pretreated with normal serum (control) or anti-secretin serum. "
01/01/1985 - "Young (6 month old) and aged (26 months old) male Sprague-Dawley rats were prepared with pancreatic fistulas and challenged with different doses of secretin (0.03, 0.06, and 0.12 nmol/kg) and cholecystokinin-8 (0.3, 0.6, and 1.2 nmol/kg) intravenously. "
03/01/1982 - "1. In dogs with chronic gastric and pancreatic fistulas, a liver extract meal adjusted to various pH levels ranging from 7.0 to 2.0, was introduced into the stomach and the increments in plasma secretin levels were correlated with the pH of the liver extract meal and pancreatic bicarbonate outputs. "
05/01/1981 - "4. Secretin infusion or feeding a meat meal produced a similar rate of pancreatic bicarbonate secretion in dogs with chronic pancreatic fistula. "
01/01/1980 - "In six dogs with pancreatic fistulas, secretin (500 ng . "
04/01/2004 - "In this preliminary study, occlusion of pancreatic fistulas by using N-butyl-2-cyanoacrylate glue was safe and effective, and obviated the need for surgery in a substantial proportion of patients. "
04/01/2004 - "Further studies of the use of N-butyl-2-cyanoacrylate for closure of pancreatic fistula are warranted."
04/01/2004 - "Twelve patients with pancreatic fistulas underwent endoscopic injection of N-butyl-2-cyanoacrylate into the fistulous tract, in addition to endoscopic drainage. "
04/01/2004 - "A novel endoscopic approach to sealing pancreatic fistulas by using N-butyl-2-cyanoacrylate is described. "
04/01/2004 - "Endoscopic sealing of pancreatic fistula by using N-butyl-2-cyanoacrylate."
04/01/1984 - "Postoperative morbidity as well as the incidence of the pancreatic fistula were significantly influenced by the age of the patients over 65 years (p less than 0.01 and less than 0.001, respectively), and by the serum bilirubin level over 6 mg/dl (p less than 0.002). "
06/01/2015 - "In a multivariate analysis, DGE was influenced by retrocolic reconstruction, as well as older age, chronic pancreatitis, preoperative bilirubin level, a history of previous upper abdominal surgery, and postoperative pancreatic fistula. "
01/01/2014 - "The results of multivariate analysis showed pancreatic tube diameter < 3 mm (OR = 5.748), preoperative total bilirubin level > 171 µmol/L (OR = 5.112), duration of preoperative jaundice > 8 weeks (OR = 5.090), preoperative albumin level < 30 g/L (OR = 4.464) were independent risk factors of pancreatic fistula (all P < 0.05). "
05/01/1985 - "The incidence of the pancreatic fistula is significantly influenced by a patient age of over 65 years, a preoperative serum bilirubin level exceeding 6 mg %, urgent degree of the intervention, presence of a renal insufficiency and last but not least by the poor quality of the pancreatic remnant. "
01/01/2007 - "The secondary outcomes were complications such as cholangitis, pancreatitis, bleeding, pancreatic fistula, intra-abdominal abscess, improvement in bilirubin, and quality of life. "
09/01/2014 - "[Perioperative treatment with pasireotide reduces the rate of postoperative pancreatic fistula]."
08/28/2014 - "Pasireotide for postoperative pancreatic fistula."
08/28/2014 - "Pasireotide for postoperative pancreatic fistula."
05/22/2014 - "Pasireotide for postoperative pancreatic fistula."
05/22/2014 - "Perioperative treatment with pasireotide decreased the rate of clinically significant postoperative pancreatic fistula, leak, or abscess. "
01/01/2012 - "Despite significant improvements in the safety and efficacy of pancreatic surgery, pancreaticoenteric anastomosis continues to be the "Achilles heel" of pancreaticoduodenectomy, due to its association with a measurable risk of leakage or failure of healing, leading to pancreatic fistula. "
05/01/2015 - "A decrease in the rate of em-TP is likely to reflect improved peri-operative management of a pancreatic fistula and its complications after a pancreaticoduodenectomy."
01/01/2012 - "To evaluate the efficacy of transanastomotic pancreatic duct internal stenting in the reduction of postoperative pancreatic fistula (POPF) after pancreaticoduodenectomy. "
11/01/2009 - "To review the current evidence on the efficacy of various interventions directed toward prevention of pancreatic fistula after pancreatoduodenectomy. "
09/01/2008 - "Efficacy of a Blake drainR on pancreatic fistula after pancreaticoduodenectomy."
04/01/2009 - "Pancreatogastrostomy is superior to pancreaticojejunostomy in terms of relevant postoperative pancreatic fistula."
10/01/2009 - "Pancreatic anastomosis modified according to the pancreatic anatomy is effective in reducing the risk of pancreatic fistula formation with end-to-side, duct-to-mucosa pancreaticojejunostomy after pancreatic head resection."
09/01/2014 - "The effects of duct-to-mucosa pancreaticojejunostomy (dmPJ) and invaginating pancreaticojejunostomy (iPJ) on postoperative complication in five studies were compared, and no statistical significance were found in postoperative pancreatic fistula (POPF) (M-H:OR = 0.77, 95% CI:0.35-1.69, P = 0.52), reoperation (M-H:OR = 1.38, 95% CI:0.64-2.95, P = 0.41) and mortality (M-H:OR = 1.15, 95% CI:0.42-3.13, P = 0.79) between dmPJ and iPJ. "
01/01/2012 - "The trial hypothesis is that postoperative pancreatic fistula rate is lower after pancreatogastrostomy when compared to pancreatojejunostomy. "
07/01/2011 - "The purpose of this study was to identify basic risk factors for postoperative pancreatic fistula (POPF) after pancreaticojejunostomy. "
10/01/1998 - "Optimal treatment strategies for patients with external pancreatic fistulas have evolved with improved radiographic imaging and the development of transpapillary pancreatic duct stents. "
01/01/2011 - "The meta-analysis revealed that the use of an external pancreatic duct stent was associated with a statistically significant reduction in overall postoperative morbidity (OR 0.56; 95% CI 0.39-0.81; p = 0.002), pancreatic fistula (OR 0.34; 95% CI 0.23-0.15; p < 0.001), severity of pancreatic fistula (OR 0.70; 95% CI 0.32-1.57; p = 0.04), delayed gastric emptying (OR 0.44; 95% CI 0.25-0.80; p = 0.007), and length of hospital stay (WMD -3.95; 95% CI -6.38 to -1.52; p = 0.001). "
05/01/2013 - "The efficacy of pancreaticojejunal (P-J) anastomotic stents in preventing clinically relevant postoperative pancreatic fistulas (CR-POPF) after pancreatic resection is poorly understood. "
06/01/2012 - "Clinically significant PF (ISGPF [The International Study Group on Pancreatic Fistula] classification Grade B or C) occurred in 6 DP (22.2%) and 11 (42.3%) DP + stent patients (odds ratio: 2.57, 95% confidence interval 0.78-8.48; P = 0.122). "
01/01/2012 - "The clinically relevant POPF (International Study Group on Pancreatic Fistula definition grade B or C) rates in the stent and no-stent groups were similar (9.6% [43 of 449 patients] and 12.5% [13 of 104 patients], respectively; P = .38). "
01/01/2013 - "Distal pancreatectomy with the use of the TL60 stapler eliminated the risk of pancreas-related factors for the occurrence of clinically relevant pancreatic fistula."
07/01/2011 - "Duct-to-mucosa pancreaticogastrostomy may be a safe and effective technique for preventing pancreatic fistula development after distal pancreatectomy when performed by experienced surgeons who are skilled in this technique."
01/01/2013 - "Incidence of pancreatic fistula after distal pancreatectomy and efficacy of endoscopic therapy for its management: results from a tertiary care center."
08/01/2012 - "Improved rate of pancreatic fistula after distal pancreatectomy: parenchymal division with the use of saline-coupled radiofrequency ablation."
07/01/2011 - "We evaluated the safety and efficacy of duct-to-mucosa pancreaticogastrostomy for preventing pancreatic fistula development after distal pancreatectomy. "
06/01/2002 - "Pancreatic fistula, the most serious complication of the Whipple procedure, can be almost entirely eliminated by a technique that combines meticulous attention to placement and tying of sutures under magnification with optimization of blood supply to the anastomosis."
01/01/2015 - "The double-layer continuous suturing after PD is safe, reliable, rapid, favorable and associated with a lower risk of pancreatic fistula than the double layer interrupted suture."
01/01/2015 - "The presence of Grade C pancreatic fistulas was only documented in one patient in the double layer continuous suture group and 3 patients in the interrupted suture group. "
01/01/2015 - "Pancreatic fistulas occurred in patients with double layer continuous suture was 17.14%(6/35), and in those with interrupted suture was 39.24%(31/79) (p<0.05). "
09/01/2013 - "There was no significant difference in the incidence of pancreatic fistula between the 3 types of stump closure (hand-sewn suture [44%] vs bipolar scissors [37.7%] vs stapler closure [35.5%]). "